Wang et al. [22] confirmed that GBP2 could regulate PD-L1 expression via STAT1 signaling in colorectal cancer, and patients with high GBP2 expression can have a better response to anti-PD-1 therapy [22]. Here, PDCD1 is linked to colorectal cancer.